Entrada Therapeutics, Inc. (TRDA): Price and Financial Metrics

Entrada Therapeutics, Inc. (TRDA): $13.10

0.95 (+7.82%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add TRDA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#19 of 360

in industry

TRDA Price/Volume Stats

Current price $13.10 52-week high $18.44
Prev. close $12.15 52-week low $10.62
Day low $12.20 Volume 119,000
Day high $13.13 Avg. volume 79,356
50-day MA $13.27 Dividend yield N/A
200-day MA $14.75 Market Cap 440.17M

TRDA Stock Price Chart Interactive Chart >


Entrada Therapeutics, Inc. (TRDA) Company Bio


Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.


TRDA Latest News Stream


Event/Time News Detail
Loading, please wait...

TRDA Latest Social Stream


Loading social stream, please wait...

View Full TRDA Social Stream

Latest TRDA News From Around the Web

Below are the latest news stories about ENTRADA THERAPEUTICS INC that investors may wish to consider to help them evaluate TRDA as an investment opportunity.

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Yahoo | December 28, 2023

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.

Yahoo | December 28, 2023

Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares

Kory Wentworth, the CFO of Entrada Therapeutics Inc (NASDAQ:TRDA), executed a sale of 12,500 shares in the company on December 26, 2023, according to a recent SEC Filing.

Yahoo | December 28, 2023

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

Yahoo | December 26, 2023

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Yahoo | December 26, 2023

Read More 'TRDA' Stories Here

TRDA Price Returns

1-mo -4.52%
3-mo -15.37%
6-mo -5.79%
1-year -6.83%
3-year N/A
5-year N/A
YTD -13.19%
2023 11.61%
2022 -21.03%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!